prikaz prve stranice dokumenta Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
  Download
PDF 713.07 KB
Scientific paper - Original scientific paper
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
Multiple Sclerosis Journal, 25 (2019), 9; 1273-1288. https://doi.org/10.1177/1352458519841829
Phelps, Richard; Winston, Jonathan A; Wynn, Daniel; Habek, Mario; Hartung, Hans-Peter; Havrdová, Eva Kubala; Markowitz, Glen S; Margolin, David H; Rodriguez, Claudio E; Baker, Darren P; Coles, Alasdair J

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Phelps, R., Winston, J. A., Wynn, D., Habek, M., Hartung, H. P., Havrdová, E. K. ... Coles, A. J. (2019). Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 25. (9), 1273-1288. doi: 10.1177/1352458519841829

Phelps, Richard, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal, vol. 25, no. 9, 2019, pp. 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, Richard, Jonathan A Winston, Daniel Wynn, Mario Habek, Hans Peter Hartung, Eva Kubala Havrdová, Glen S Markowitz, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal 25, no. 9 (2019): 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, R., et al. (2019) 'Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis', Multiple Sclerosis Journal, 25(9), pp. 1273-1288. doi: 10.1177/1352458519841829

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, and sur.. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal [Internet]. 2019 August [cited 2024 April 29];25(9):1273-1288. doi: 10.1177/1352458519841829

R. Phelps, et al., "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis", Multiple Sclerosis Journal, vol. 25, no. 9, pp. 1273-1288, August 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:942822. [Accessed: 29 April 2024]

Metadata
Title (english)Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
AuthorRichard Phelps
AuthorJonathan A Winston
AuthorDaniel Wynn
AuthorMario Habek
AuthorHans-Peter Hartung
AuthorEva Kubala Havrdová
AuthorGlen S Markowitz
AuthorDavid H Margolin
AuthorClaudio E Rodriguez
AuthorDarren P Baker
AuthorAlasdair J Coles
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Background: Autoimmune disorders including nephropathies have been reported more frequently in alemtuzumab-treated multiple sclerosis (MS) patients than in the general population. ----- Objective: Describe instances of autoimmune nephropathy in alemtuzumab-treated MS patients. ----- Methods: Cases were identified from safety monitoring within the alemtuzumab relapsing-remitting multiple sclerosis (RRMS) clinical development program (CDP) or post-marketing, or following off-label use. ----- Results: As of 16 June 2017, 16 autoimmune nephropathies have occurred following alemtuzumab treatment for MS. The incidence of autoimmune nephropathies was 0.34% within the CDP (5/1485 patients). The five CDP cases (one of anti-glomerular basement membrane (anti-GBM) disease, two of membranous glomerulonephropathy, and two of serum anti-GBM antibody without typical anti-GBM disease) were identified early, responded to conventional therapy (where needed), and had favorable outcomes. Three of 11 cases outside the CDP occurred following off-label alemtuzumab use prior to approval for RRMS and were all anti-GBM disease. Diagnosis was delayed in one of these three cases and another did not receive appropriate treatment; all three cases resulted in end-stage renal failure. All anti-GBM disease cases with documented urinalysis demonstrated prior microscopic hematuria. ----- Conclusion: Close monitoring of alemtuzumab-treated MS patients facilitates diagnosis and treatment early in the nephropathy course when preservation of renal function is more likely.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMultiple Sclerosis Journal
Numberingvol. 25, no. 9, pp. 1273-1288
p-ISSN1352-4585
DOIhttps://doi.org/10.1177/1352458519841829
URN:NBNurn:nbn:hr:105:942822
Publication2019-08
Document URLhttp://doi.org/10.1177/1352458519841829
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:34:55